Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
25 GBX | -1.96% | -16.67% | +61.29% |
Apr. 18 | Renalytix chief business officer to become president | AN |
Apr. 18 | Renalytix Names Chief Business Officer as President | MT |
Financials (USD)
Sales 2024 * | 4M | Sales 2025 * | 18M | Capitalization | 40.64M |
---|---|---|---|---|---|
Net income 2024 * | -35M | Net income 2025 * | -26M | EV / Sales 2024 * | 10.2 x |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 2.26 x |
P/E ratio 2024 * |
-
| P/E ratio 2025 * |
-
| Employees | 102 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 53.5% |
Latest transcript on Renalytix Plc
1 day | -1.96% | ||
1 week | -16.67% | ||
Current month | -25.37% | ||
1 month | -28.57% | ||
3 months | +112.77% | ||
6 months | -39.02% | ||
Current year | +61.29% |
Managers | Title | Age | Since |
---|---|---|---|
James McCullough
FOU | Founder | 56 | 18-03-14 |
James Sterling
DFI | Director of Finance/CFO | 54 | 18-03-14 |
Thomas McLain
PSD | President | 66 | 19-07-28 |
Members of the board | Title | Age | Since |
---|---|---|---|
Daniel Levangie
BRD | Director/Board Member | 73 | 21-08-29 |
Chairman | 72 | 18-03-14 | |
James McCullough
FOU | Founder | 56 | 18-03-14 |
Date | Price | Change | Volume |
---|---|---|---|
24-04-26 | 25 | -1.96% | 57 758 |
24-04-25 | 25.5 | -3.77% | 43,867 |
24-04-24 | 26.5 | -3.64% | 105,921 |
24-04-23 | 27.5 | -5.17% | 248,283 |
24-04-22 | 29 | -3.33% | 4,852 |
Delayed Quote London S.E., April 26, 2024 at 05:31 am EDT
More quotesQuarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+61.29% | 40.64M | |
-13.21% | 18.55B | |
-46.15% | 2.65B | |
+14.09% | 1.81B | |
-3.39% | 1.61B | |
+21.69% | 1.21B | |
-10.58% | 1.03B | |
-21.72% | 896M | |
-8.25% | 680M | |
-17.56% | 686M |
- Stock Market
- Equities
- RENX Stock